Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.
The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.
The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.
The conversation discusses the use of finasteride and minoxidil for hair loss, with skepticism about the effectiveness of a supplement called Halo Elite. Users express doubt about the supplement's benefits, suggesting it may be a placebo.
This study concluded that label-retaining cells in mouse epidermis differ in their sensitivity to proliferative stimuli, influencing their division and potential transdifferentiation without consistently depleting their population.
37 citations
,
December 2014 in “Journal of Biomedical Informatics”
This study introduced LabeledIn, a semi-automatic, human-reviewed catalog of drug-disease treatment relationships, highlighting the important role of human input in creating accurate and detailed drug indication resources.
This study found that sweat gland stem cells primarily maintain sweat gland homeostasis but can trans-differentiate to aid in epidermal healing and regenerate diverse skin structures under certain conditions.
35 citations
,
January 1993 in “International Journal of Dermatology”
In this study, most hair disorders among HIV-1 positive patients were associated with low helper T cell counts, with papulosquamous conditions like seborrheic dermatitis and psoriasis being the most common.
Dutasteride side effects: what the label and studies actually reportThe Avodart label reports impotence in 4.7% and decreased libido in 3.0% of men in the first six months (1.7% and 1.4% on placebo), with new reports falling after month six; those figures come from BPH trials in older men, and the hair-loss trials in younger men run only six months. The label and studies also flag a PSA drop of about half, a small rise in high-grade prostate cancer in one trial, an observational link to depression, and sexual effects that the label says may persist after stopping.